EUVIMEDEUVIMED entdecken
Open Access

Artificial Intelligence–Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy

Magdalena Fay iD, Ross S Liao iD, Zaeem M Lone iD, Chandana A Reddy iD, Hassan Muhammad, Chensu Xie, Parag Jain, Wei Huang iD, Hirak S Basu iD, Sujit S Nair iD, Dimple Chakravarty, Sean R Williamson iD und 7 weitere

JCO Clinical Cancer Informatics · 2025

DOI: 10.1200/cci-24-00292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Magdalena Fay und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Lerner College of Medicine, Cleveland, OH. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Artificial Intelligence. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Artificial intelligence (AI) tools that identify pathologic features from digitized whole-slide images (WSIs) of prostate cancer (CaP) generate data to predict outcomes. The objective of this study was to evaluate the clinical validity of an AI-enabled prognostic test, PATHOMIQ_PRAD, using a clinical cohort from the Cleveland Clinic. METHODS We conducted a retrospective analysis of PATHOMIQ_PRAD using CaP WSIs from patients who underwent radical prostatectomy (RP) between 2009 and 2022 and did not receive adjuvant therapy. Patients also had Decipher genomic testing available. WSIs were deidentified, anonymized, and outcomes were blinded. Patients were stratified into high-risk and low-risk categories on the basis of predetermined thresholds for PATHOMIQ_PRAD scores (0.45 for biochemical recurrence [BCR] and 0.55 for distant metastasis [DM]). RESULTS The study included 344 patients who underwent RP with a median follow-up of 4.3 years. Both PathomIQ and Decipher scores were associated with rates of biochemical recurrence-free survival (BCRFS; PathomIQ score >0.45 v ≤0.45, P 0.6 v ≤0.6, P = .002). There were 16 patients who had DM, and 15 were in the high-risk PathomIQ group (Mets Score >0.55). Both PathomIQ and Decipher scores were associated with rates of metastasis-free survival (PathomIQ score >0.55 v ≤0.55, P 0.6 v ≤0.6, P = .0052). Despite the low event rates for metastasis, multivariable regression demonstrated that high PathomIQ score was significantly associated with DM (>0.55 v ≤0.55, hazard ratio, 10.10 [95% CI, 1.28 to 76.92], P = .0284). CONCLUSION These findings independently validate PATHOMIQ_PRAD as a reliable predictor of clinical risk in the postprostatectomy setting. PATHOMIQ_PRAD therefore merits prospective evaluation as a risk stratification tool to select patients for adjuvant or early salvage interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyArtificial IntelligenceHumansMaleMiddle AgedAgedRetrospective StudiesPrognosisRisk AssessmentNeoplasm GradingFollow-Up Studies

Autor:innen und Institutionen

  • Cleveland Clinic Lerner College of Medicine, Cleveland, OH.
  • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • PathomIQ Inc, Cupertino, CA.
  • Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.
  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

ORCID-Profile: Magdalena Fay, Ross S Liao, Zaeem M Lone, Chandana A Reddy, Wei Huang, Hirak S Basu, Sujit S Nair, Sean R Williamson, Shilpa Gupta, George Wilding, Eric A Klein, Omar Y Mian

Förderung

  • NCI NIH HHS

Zitieren

APA

Fay, M., Liao, R. S., Lone, Z. M., Reddy, C. A., Muhammad, H., Xie, C., Jain, P., Huang, W., Basu, H. S., Nair, S. S., Chakravarty, D., Williamson, S. R., Gupta, S., Weight, C., Roy, R., Wilding, G., Tewari, A. K., Klein, E. A., & Mian, O. Y. (2025). Artificial Intelligence–Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00292

Vancouver

Fay M, Liao RS, Lone ZM, Reddy CA, Muhammad H, Xie C, et al. Artificial Intelligence–Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00292

BibTeX
@article{Fay2025,
  author = {Fay, Magdalena and Liao, Ross S and Lone, Zaeem M and Reddy, Chandana A and Muhammad, Hassan and Xie, Chensu and Jain, Parag and Huang, Wei and Basu, Hirak S and Nair, Sujit S and Chakravarty, Dimple and Williamson, Sean R and Gupta, Shilpa and Weight, Christopher and Roy, Rajat and Wilding, George and Tewari, Ashutosh K and Klein, Eric A and Mian, Omar Y},
  title = {Artificial Intelligence–Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy},
  journal = {JCO Clinical Cancer Informatics},
  year = {2025},
  doi = {10.1200/cci-24-00292}
}
Kostenlos starten →